Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS ...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Invega Hafyera (6-month Paliperidone Palmitate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 11, 2021 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, ...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

Invega Hafyera (6-month Paliperidone Palmitate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Invega Hafyera (paliperidone palmitate) for Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic Invega Hafyera (6-month paliperidone... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia
The FDA has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera) for adults with schizophrenia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2021 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These ac...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

An accidental household outbreak of paliperidone palmitate poisoning via pancake consumption in Lianyungang, China - Zhang T, Li Z, Luo P, Sun Q.
INTRODUCTION: At 11:20 on 26 May 2018, a physician from Lianyungang No. 1 People's Hospital, China, reported that six family members were being treated in the hospital with symptoms from an unknown cause. METHODS: A case series for a food poisoning... (Source: SafetyLit)
Source: SafetyLit - May 31, 2021 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Jo...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

CHMP Backs Generic Paliperidone for Schizophrenia CHMP Backs Generic Paliperidone for Schizophrenia
Paliperidone Janssen-Cilag International, a generic of Xeplion, is for maintenance treatment of schizophrenia in adults stabilized with paliperidone or risperidone and select other cases.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 2, 2020 Category: Consumer Health News Tags: Psychiatry News Source Type: news